MX2023000351A - Agente ahorrador de glucocorticoides. - Google Patents

Agente ahorrador de glucocorticoides.

Info

Publication number
MX2023000351A
MX2023000351A MX2023000351A MX2023000351A MX2023000351A MX 2023000351 A MX2023000351 A MX 2023000351A MX 2023000351 A MX2023000351 A MX 2023000351A MX 2023000351 A MX2023000351 A MX 2023000351A MX 2023000351 A MX2023000351 A MX 2023000351A
Authority
MX
Mexico
Prior art keywords
glucocorticoid
sparing agent
sparing
agent
phthalazinedione
Prior art date
Application number
MX2023000351A
Other languages
English (en)
Inventor
Wolfgang Brysch
Wegerer Jörg Von
Astrid Kaiser
Petra Schulz
Sara Schumann
Beate Ludescher
Original Assignee
Metriopharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metriopharm Ag filed Critical Metriopharm Ag
Publication of MX2023000351A publication Critical patent/MX2023000351A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

5-amino-2,3-dihidro-1,4-ftalazindiona o una de sus sales farmacéuticamente aceptables para su uso como agente ahorrador de corticoides y combinaciones farmacéuticas que comprenden dicho agente ahorrador de glucocorticoides y un glucocorticoide para su uso en la profilaxis y/o tratamiento de condiciones o enfermedades tratadas habitualmente con glucocorticoides, así como formas de aplicación adecuadas, composiciones farmacéuticas y sus usos profilácticos o terapéuticos.
MX2023000351A 2020-07-09 2021-07-08 Agente ahorrador de glucocorticoides. MX2023000351A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20000248 2020-07-09
PCT/EP2021/000078 WO2022008093A1 (en) 2020-07-09 2021-07-08 Glucocorticoid-sparing agent

Publications (1)

Publication Number Publication Date
MX2023000351A true MX2023000351A (es) 2023-05-19

Family

ID=71574915

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000351A MX2023000351A (es) 2020-07-09 2021-07-08 Agente ahorrador de glucocorticoides.

Country Status (12)

Country Link
US (1) US20230241060A1 (es)
EP (1) EP4178579A1 (es)
JP (1) JP2023532972A (es)
KR (1) KR20230038228A (es)
CN (1) CN115916258A (es)
AU (1) AU2021304254A1 (es)
BR (1) BR112023000287A2 (es)
CA (1) CA3183225A1 (es)
IL (1) IL299528A (es)
MX (1) MX2023000351A (es)
WO (1) WO2022008093A1 (es)
ZA (1) ZA202300309B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11918570B2 (en) 2020-04-13 2024-03-05 The Research Foundation For The State University Of New York Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition
WO2023131579A1 (en) * 2022-01-07 2023-07-13 Metriopharm Ag Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of congenital muscular dystrophies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953799B1 (en) 2002-10-30 2005-10-11 Bach Pharma, Inc. Modulation of cell fates and activities by diketo phthalazines
US7326690B2 (en) 2002-10-30 2008-02-05 Bach Pharma, Inc. Modulation of cell fates and activities by phthalazinediones
PL231885B1 (pl) 2009-01-16 2019-04-30 Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie
CN102971300B (zh) 2010-03-01 2016-03-02 梅特里奥药品股份公司 5-氨基-2,3-二氢-(2,3-二氮杂萘)-1,4-二酮钠盐的晶型、含有它们的药物制剂以及所述晶型的生产方法
AU2012232670A1 (en) 2011-03-23 2013-09-12 Ariel-University Research And Development Company Ltd. Treatment of proliferative disorders with a chemiluminescent agent
WO2016096143A1 (de) 2014-12-18 2016-06-23 Metriopharm Ag Kristalline form von 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
EP3248602A1 (en) * 2016-05-26 2017-11-29 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the tendons, ligaments of the joints, articular capsules and bursae
PL3534904T3 (pl) * 2016-11-07 2022-07-18 Metriopharm Ag Zastosowanie 5-amino-2,3-dihydro-1,4-ftalazynodionu w leczeniu przewlekłego postępującego stwardnienia rozsianego

Also Published As

Publication number Publication date
ZA202300309B (en) 2024-05-30
US20230241060A1 (en) 2023-08-03
CN115916258A (zh) 2023-04-04
BR112023000287A2 (pt) 2023-01-31
AU2021304254A1 (en) 2023-02-16
JP2023532972A (ja) 2023-08-01
EP4178579A1 (en) 2023-05-17
IL299528A (en) 2023-02-01
KR20230038228A (ko) 2023-03-17
CA3183225A1 (en) 2022-01-13
WO2022008093A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
ZA202300309B (en) Glucocorticoid-sparing agent
MX2022009164A (es) N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos.
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
WO2020115555A3 (en) Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
CR20220570A (es) Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas
MX2023011326A (es) Composiciones de psilocibina, metodos para prepararlas y metodos de uso de estas.
PH12019502086A1 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
MX2021004207A (es) Uso de reboxetina para el tratamiento de narcolepsia.
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
WO2023081830A3 (en) Compositions and treatments with nirogacestat
MX2024000043A (es) Compuestos inhibidores de la caspasa-2.
ZA202212095B (en) Il4i1 inhibitors and methods of use
MX2023014563A (es) Combinacion de un inhibidor de braf particular (interruptor de paradoja) y un antagonista de union al eje de pd-1 para su uso en el tratamiento de cancer.
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023005462A (es) Compuestos macrociclicos y metodos para usarlos.
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
MX2022005250A (es) Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b.
EP3733203A4 (en) PROPHYLACTIC AGENT AND / OR THERAPEUTIC AGENT FOR CATARACT, MEDICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF CATARACT, USE OF PPAR ACTIVATOR TO MAKE IT AND EYE DROPS
MX2020007062A (es) Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas.
HUP0202638A2 (hu) Fermentált búzacsíra-kivonat alkalmazása gyulladáscsökkentő készítmények előállítására
MX2023010545A (es) Inhibidores de integrinas alfa v beta 6 y alfa v beta 1 y usos de los mismos.
MX2022012001A (es) Tratamiento preventivo de la migra?a.